| Biomarker ID | 1371 |
| PMID | 24708576 |
| Year | 2014 |
| Biomarker | CCND1 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate: HR: 1.38 (95% CI: 1.01-1.88) |
| Effect on Pathways | Pathways include: Myc repressed pathway, Chronic myeloid leukemia, Cyclin A-Cdk2-associated events at S phase entry, Melanoma, Viral myocarditis |
| Experiment | Biochemical Failure Vs No Biochemical Faliure |
| Type of Biomarker | Prognostic |
| Cohort | 160 patients with PCa were selected for the analysis |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.042 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | Time to BF was calculated from date of prostatectomy to the date of known BF, defined as the date of a PSA value ≥0.2 ng/mL (taken at least 6 weeks after surgery) and confirmed by a second PSA value >0.2 ng/mL. Time to BF was censored at the last date of contact for subjects who did not experience BF. |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |